Remote Patient Monitoring – Opportunities for Pharma – Thematic Research

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Remote patient monitoring (RPM) relies on digital health technologies and connected devices to record vital signs and relay data and information to patients, careers, and physicians or healthcare teams. RPM enables clinicians to track patients in real time through a clinician dashboard or directly within a patient’s electronic health record (EHR), allowing timely intervention if necessary. RPM also gives patients more control over their health and a sense of empowerment, while improving health outcomes. The use of RPM has gained significant traction since the beginning of the COVID-19 pandemic in early 2020, with increased demand for alternatives to in-person care as a result of social distancing and lockdown measures. The different types of RPM technologies, such as wearables, mHealth, and telemedicine, have been tapped by the pharmaceutical industry for use across its value chain from drug development through post-marketed strategies.

Wearable devices: Wearable devices are becoming increasingly disease-oriented, as medical devices is one of the fastest growing areas in the life sciences. As such, medical device companies are shifting their interest from consumables to disease/care management services and products. Wearable tech is becoming more advanced, with better battery life and multiple sensors driving more complex and capable devices, accelerated by ever-smarter algorithms powered by artificial intelligence (AI) and machine learning (ML).

mHealth: As part of telehealth, mHealth utilizes mobile technology and smart devices to achieve improved health objectives and outcomes, healthcare services, and research. Increasing network coverage and newer devices and software offer novel opportunities for integration into existing health systems, placing mHealth technologies in a good position to promote quality healthcare. Additionally, mHealth can be applied across clinical research to improve drug discovery and development through to post-market surveillance, as well as directly by consumers.

Telemedicine: Telemedicine became an invaluable tool during the COVID-19 pandemic, allowing patients to connect with and receive care from their HCPs while maintaining safety and minimizing transmission risk. Telemedicine has also been used to mitigate the disruption seen to clinical trials, allowing participants to engage and communicate with investigators and other research staff from the comfort of their own home.

What are the key technology trends impacting the remote patient monitoring market?

Increased interest and activity in RPM solutions:  There has been an increase in applications using IoT sensors seeing adoption by hospitals, surgical centers, medical care centers, CROs, and research/diagnostic laboratories. RPM is just one application of IoT sensors in healthcare, and as the population of digitally savvy users who own smartphones and personalized hardware grows, the feasibility of RPM becomes more likely.

Wearables and the collection of health data: Wearable tech in healthcare gives patients the power to track their health at home through things like smartwatches, biometric clothing, e-skin, and biosensors. Currently, the largest market in this space is activity monitors, which is being driven by the sports and fitness segment. However, these devices have expanded significantly within the healthcare market, gaining regulatory approval as medical-grade devices.

Increased availability of mHealth apps: The variety of mHealth tools available to capture patient data is expanding rapidly, as publicly available apps are becoming ubiquitous and a large portion of the population in the US and Europe own smartphones. These mHealth apps offer to help disease management, RPM, and medication adherence across disease indications.

Big Data and AI will continue to dominate as transformational forces in healthcare: The generation of big data enables better monitoring of disease and insights into disease risk prediction and earlier detection, which is especially relevant for neurological conditions that rely on diagnoses that often occur at a late stage when little intervention is possible. Big Data and AI-powered analysis tools can also be used in pharmaceutical research and healthcare service delivery across a spectrum of digital health technologies, and more widely across processes ranging from target identification to commercialization activities. It will eventually reduce R&D cycle time and costs, paving the way to stronger and more sustainable drug pipelines.

Cybersecurity: As the healthcare industry becomes more digitized, there are more avenues for cybercriminals to steal personal and proprietary data, including from medical health records and connected medical devices. Connected devices that collect personal health data, such as wearables, frequently exchange data with paired devices via Bluetooth, which makes them especially susceptible to hacking. Thus, all digital health vendors have recently stepped up their efforts to enforce encryption standards recommended by the Bluetooth Special Interest Group. There is a competing need for enhanced cybersecurity for large healthcare companies and smaller digital health players to ensure cybersecurity and patient safety risks are taken into consideration.

What is the value chain for remote patient monitoring market?

The RPM can be adopted across the entire pharma value chain to various ends. For example, mHealth, wearables, RPM, and telemedicine impact most of the pharma value chain from drug discovery and development, drug approval, and post approval, all the way through to sales and marketing, as well as directly to patients.

The remote monitoring technologies can be used across the pharma value chain:

  • Drug discovery and development
  • Drug approval & post approval
  • Manufacturing & supply chain
  • Sales & marketing
  • Patients

Which are key companies in the remote patient monitoring market?

Key companies in the remote patient monitoring are AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Biogen, BMS, Eli Lilly, Gilead, GSK, J&J, Merck & Co., Novartis and Novo Nordisk.

Market report scope

Key companies AbbVie, Amgen, Astellas, AstraZeneca, Bayer, Biogen, BMS, Eli Lilly, Gilead, GSK, J&J, Merck & Co., Novartis and Novo Nordisk

Scope

  • Key players in the RPM space, with a focus on technology providers and pharma adopters where applicable. The report focuses on any remote monitoring technologies that big pharma has integrated into RPM projects and solutions.
  • Thematic briefing which explores different types of RPM in more detail, including wearables, portable devices, mHealth, and telemedicine.
  • Key trends impacting the RPM space. Industry trends include the impact of COVID-19 on clinical trials and digital health innovation, how RPM is driving value-based care and increased patient empowerment, and the impact of increased burden of chronic diseases. Technology trends include the role of wearable technology, mHealth, telemedicine, Big Data and artificial intelligence (AI), and cybersecurity. Regulatory trends include the lack of regulatory frameworks for virtual trials and guidelines issues during COVID-19 to support continuation of clinical research.
  • Opportunities and challenges for pharma: Opportunities include such changing regulations, continued acceptance of digital technologies, increased collaborations, patient support programs, and value-based care. Challenges include data privacy and security, interoperability, design challenges, and skills shortages.
  • Value chain looking at how RPM can be used across the pharma value chain, from drug discovery and development, post drug approval, sales and marketing, and patient use.
  • Industry analysis with an analysis of virtual trials including those generating real-world evidence, use of telemedicine during the pandemic, analysis of mobile apps from pharma, as well comprehensive deals, jobs, and Influencer analyses. This section also includes case studies and survey and poll data.
  • Profiles of private and public companies in the RPM space.

Reasons to Buy

  • Assess who the leading technology players are in the RPM space, as well as leading pharma adopters.
  • See examples of how pharma companies are integrating remote monitoring technologies into their value chains.
  • Understand what trends are driving the use of RPM, and also what opportunities and challenges exist for pharma in the space.
  • See how the RPM landscape is evolving, with a review of company activity including mergers and acquisitions (M&A), strategic partnerships and funding deals, as well as a jobs analysis.
  • Assess the impact of COVID-19 on the use of remote monitoring technologies by physicians.

Johnson & Johnson
Pfizer
Roche
Novartis
Takeda
AbbVie
AstraZeneca
Sanofi
GlaxoSmithKline
Eli Lilly
AliveCor
Empatica
Livongo
Omron
Teladoc
Amwell
Aural Analytics
Evidation
Huma
Science37
Medable
THREAD
AiCure
Akili
Babylon
Biobeat
Qardio
Biofourmis
Thirty Madison
Doctolib
Lightship
Studies&Me

Table of Contents

Executive Summary

Players

Thematic Briefing

Trends

• Healthcare Trends

• Technology Trends

• Regulatory trends

• Macroeconomic Trends

Opportunities and Challenges for Pharma

Value Chain

• Drug Discovery and Development

• Post Drug Approval

• Sales and Marketing

• End Users

Industry Analysis

• Virtual Clinical Trials Analysis

• Use of RPM-Derived Real-World Evidence in Post-Marketing Studies

• Increased Use of Telemedicine During the COVID-19 Pandemic

• Analysis of Mobile Apps from Pharma

• Analysis of RPM-Related Jobs in Pharma

• Physician Trends in Remote Monitoring Technologies and the Impact of COVID-19 on Usage

• Deals Analysis

o Mergers and Acquisitions

o Strategic Partnerships

o Funding Deals

• Pharma Case Studies

o Genentech Telemedicine-Based Patient Support Programs

o Evidation and Merck: Digital Monitoring with Focus on Alzheimer’s Disease

o Biobeat Collaborates with Amwell and Amgen to Offer Comprehensive Wearable RPM Services

o Roche Leads the Biopharmaceutical Industry in Terms of Digital Biomarker Research and Investment

• Jobs Analysis

• Healthcare Industry Polls

• Social Media Influencers

Companies

• Public Pharma Companies

• Private Pharma Companies

• Public Technology Companies

• Private Technology Companies

Appendix

• Abbreviations

• Further Reading

o Related Reports

o Bibliography

• About the Authors

• Our Thematic Research Methodology

• About GlobalData

• Contact Us

Frequently asked questions

Remote Patient Monitoring – Opportunities for Pharma – Thematic Research thematic reports
Currency USD
$995

Can be used by individual purchaser only

$1,995

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Remote Patient Monitoring – Opportunities for Pharma – Thematic Research was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Remote Patient Monitoring – Opportunities for Pharma – Thematic Research in real time.

  • Access a live Remote Patient Monitoring – Opportunities for Pharma – Thematic Research dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.